BioSpace News Archive

Ophthalmic corticosteroids are used to prevent permanent damage to the eye, which may occur with certain eye problems.

Geneva, Switzerland, March10, 2022 - Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, reported financial results for the full-year ended December 31, 2021 and provided a corporate update.

Bayer and Cinven have entered into a definitive agreement regarding the sale of Bayer’s Environmental Science Professional business for a purchase price of 2.6 billion U.S. dollars, Bayer announced on Thursday.

Abivax SA, a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, reports promising results from its phase 2a maintenance trial in rheumatoid arthritis after one year of continued daily treatment with 50mg ABX464.

UK genomics company, RevoluGen Ltd., announces that Nick McCooke, widely recognised leader in the next generation sequencing field, has been appointed as Strategic Advisor.

AlzeCure Pharma AB announced that the company is participating at the BioStock Investor Meeting on March 16 at 14:25 CET, where CEO Martin Jönsson will present the company’s latest developments, including the ongoing rights issue.

Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors, announced that the first subjects have been dosed in the company’s Phase 1, first-in-human trial of their clinical candidate CFTX-1554, a novel inhibitor of the angiotensin II type 2 receptor.

ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, announced that it will support an industry-sponsored satellite symposium titled, “Multi-disciplinary Approach to Personalized Medicine, Optimizing Therapeutic Outcomes,” at the Society of Nuclear Medicine and Molecular Imaging Therapeutics Conference, held as an in person meeting from March 10-12 in New Orleans, Louisiana, USA.

LumiThera Inc., a commercial stage medical device company offering photobiomodulation treatment for ocular damage and disease, announced the completion of a debt financing with Leste Clearway and Serengeti Asset Management.

Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced that Dr Megan Baldwin, the Company’s Chief Executive Officer, will present at Oppenheimer’s 32nd Annual Healthcare Conference, being held virtually from March 15-17, 2022.